Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 2-dose pharmacokinetic, safety, and tolerability study of eslicarbazepine acetate in infants with refractory partial-onset seizures
2012-001091-11Phase 2Completed
- Sponsor
- BIAL
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eslicarbazepine acetate in intractable epilepsy (IE), sponsored by BIAL. Started Feb 2017; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
intractable epilepsy (IE)
Beyond the preview
Go deeper on 2012-001091-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001091-11.